Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IMDX
IMDX logo

IMDX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Insight Molecular Diagnostics Inc (IMDX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.290
1 Day change
1.29%
52 Week Range
8.510
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

IMDX is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has short-term bullish technical structure, but the setup lacks strong confirmation from news, catalysts, financials, analyst upgrades, insider buying, or Intellectia proprietary signals. Given the pre-market price of 6.53 and resistance near 6.745, this is better viewed as a hold and watch rather than an immediate buy.

Technical Analysis

The current trend is constructive but not fully confirmed. MACD histogram is positive at 0.0685, which supports short-term momentum, and the moving averages are bullish with SMA_5 > SMA_20 > SMA_200. RSI_6 at 68.234 is elevated but not giving a strong overbought warning. Price is trading below first resistance at 6.745 and above pivot support at 5.996, so the stock is in an uptrend but still near a resistance zone. The probability model suggests only modest near-term upside, with a 50% chance of about 1.06% next day and limited gains over the next week and month.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mixed-to-bearish on positioning because put open interest (1034) exceeds call open interest (565), resulting in a put-call ratio of 1.83. That usually signals downside hedging or cautious sentiment. However, today's option volume is extremely light (todays_volume=2), so the flow is not strong enough to confirm a major directional bet. Implied volatility is very high at 260.01, while IV rank is 20.64 and IV percentile is 8.21, which suggests volatility is elevated in absolute terms but not especially high versus its own recent history. Overall, options data does not provide a strong bullish confirmation.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
1
Buy
9

Positive Catalysts

  • ["Bullish moving average structure: SMA_5 > SMA_20 > SMA_200", "MACD histogram remains above zero, supporting positive momentum", "Pre-market price is above the pivot level, showing some early strength", "No major negative news released in the past week"]

Neutral/Negative Catalysts

  • ["No news catalysts in the recent week", "No recent significant hedge fund or insider buying activity", "No AI Stock Picker or SwingMax signal today", "Put-call ratio of 1.83 indicates more bearish options positioning", "No recent congress trading data available", "Technical upside near-term appears limited at resistance around 6.745"]

Financial Performance

No usable financial snapshot was available due to an error, so the latest quarter season cannot be assessed from the provided data. Because of that, there is no evidence here of accelerating revenue, earnings, or margin trends to support a confident long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided. As a result, there is no visible Wall Street upgrade momentum or consensus target support. Based on the available information, the pros view is limited to technical strength, while the cons view is the lack of fundamental confirmation, weak options sentiment, and no fresh catalyst.

Wall Street analysts forecast IMDX stock price to rise
3 Analyst Rating
Wall Street analysts forecast IMDX stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 6.210
sliders
Low
8
Averages
8.5
High
9
Current: 6.210
sliders
Low
8
Averages
8.5
High
9
Lake Street
analyst
Buy
maintain
$8 -> $12
AI Analysis
2026-02-17
Reason
Lake Street
analyst
Price Target
$8 -> $12
AI Analysis
2026-02-17
maintain
Buy
Reason
Lake Street raised the firm's price target on Insight Molecular Diagnostics to $12 from $8 and keeps a Buy rating on the shares. With Insight having completed a $26M offering last week, cash on hand is now secured beyond a potential approval later this year, notes the analyst, who expects an FDA submission for GraftAssureDx in the coming weeks to be a catalyst for shares.

People Also Watch